Search - tctmd.com

Displaying 441 - 460 of 731

Sort: Relevancy | Date

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

News Daily News

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Michael O'Riordan

June 22, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

June 08, 2020

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

News Daily News

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

Michael O'Riordan

May 29, 2020

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

News Daily News

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

April 24, 2020

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.